Yukihiro Shigeta

This inventor holds 13 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Nissan Chemical Industries Limited. Active years: 2002-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yukihiro Shigeta. Retrieved from https://idiyas.com/inventor/yukihiro-shigeta

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 2)

% Patents Active = 7.7

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 19(Granted Patents)

Company Filing History:

13 out of 1,235

Nissan Chemical Industries Limited

patents

Years Active: 2002-2014

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8889732 - Fused heterocyclic compounds and thrombopoietin receptor activators (2014-11-18),

2. 8552031 - 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators (2013-10-08),

3. 8440666 - Pyridazinone compounds and P2X7 receptor inhibitors (2013-05-14),

4. 8134013 - Amide compound and thrombopoietin receptor activator (2012-03-13),

5. 8093251 - Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators (2012-01-10),

6. 8026368 - Hydrazide compounds and thrombopoietin receptor activators (2011-09-27),

7. 7968542 - Thiophene compounds and thrombopoietin receptor activators (2011-06-28),

8. 7041700 - Substituted benzopyran derivatives against arrhythmia (2006-05-09),

9. 6809114 - 4-aminobenzopyran derivatives (2004-10-26),

10. 6677371 - 4-oxybenzopyran derivative (2004-01-13),

11. 6589983 - Benzopyran derivative (2003-07-08),

12. 6555574 - 4-oxybenzopyran derivative (2003-04-29),

13. 6486178 - Indane derivatives (2002-11-26),

Title: The Innovative Contributions of Yukihiro Shigeta

Introduction

Yukihiro Shigeta is a prominent inventor based in Funabashi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that activate the thrombopoietin receptor. With a total of 13 patents to his name, Shigeta's work has the potential to impact the treatment of various diseases.

Latest Patents

Shigeta's latest patents include innovative compounds designed for the prevention and treatment of diseases where thrombopoietin receptor activation is beneficial. One of his notable inventions is a fused heterocyclic compound, which is represented by a specific formula. This compound, along with its tautomer, prodrug, or pharmaceutically acceptable salt, offers promising therapeutic applications. Another significant patent involves 3-ethylidenehydrazino substituted heterocyclic compounds, which also serve as thrombopoietin receptor activators. These compounds are similarly defined by a specific formula and hold potential for medical advancements.

Career Highlights

Yukihiro Shigeta is currently associated with Nissan Chemical Industries Limited, where he continues to innovate and develop new pharmaceutical solutions. His work is characterized by a strong focus on creating effective compounds that can lead to improved health outcomes.

Collaborations

Shigeta collaborates with esteemed colleagues in his field, including Kazufumi Yanagihara and Kazuhiko Ohrai. These partnerships enhance the research and development process, fostering an environment of innovation and creativity.

Conclusion

Yukihiro Shigeta's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key inventor. His work on thrombopoietin receptor activators showcases the potential for significant advancements in medical treatments.

Profile summary based on public USPTO records.